In today’s briefing:
- [Japan Offering] Infroneer (5076 JP) Launches New Share Offering to Pay Down M&A Debt
- Aequitas: Infroneer Holding Placement – Positives Baked In, Somewhat Flagged
- AL Robot IPO Preview
- Aequitas: Anjali LabTech Pre-IPO Tearsheet
- IPO Databook: Amicro Technology (HK) – Sep 2026
- IPO Databook: GEN Restaurant Group (GENK US) – Sep 2026
- IPO Databook: Laris Growth Acquisition (LARSU US) – Sep 2026
- IPO Databook: Acrobiosystems (301080 HK) – Sep 2026
[Japan Offering] Infroneer (5076 JP) Launches New Share Offering to Pay Down M&A Debt
- Today after the close, INFRONEER Holdings (5076 JP) announced an equity offering worth ~¥150bn at last price. Including greenshoe, it increases share count ex-Treasury by 21%.
- Max Real World Float increases nearly 60%. The goal? Pay down debt from its ¥91bn acquisition of Swing Corp and ¥9bn acquisition of Arsocia Construction (plus associated net debt).
- There are interesting parameters attached here. It is worthwhile considering how this will work.
Aequitas: Infroneer Holding Placement – Positives Baked In, Somewhat Flagged
- INFRONEER Holdings (5076 JP) aims to raise around US$800m to fund the acquisition of Swing Corporation.
- The acquisition was announced earlier this year, with the company revising its earnings a few months ago and hence, this is the last leg of the transaction.
- In this note, we will run the deal through our ECM framework.
AL Robot IPO Preview
- AL (Artificial Life) Robot is getting ready for an IPO on KOSDAQ in November. AL Robot is offering a total of 2.4 million shares.
- The IPO price range is 15,700 to 17,600 won, placing the total offering size between 37.7 billion and 42.2 billion won.
- AL Robot specializes in robot components. The company develops and supplies various components including sensors that detect a robot’s force and contact data to control units that precisely manage movement.
Aequitas: Anjali LabTech Pre-IPO Tearsheet
- Anjali Labtech Limited (ANJL IN) (ALL) plans to raise around US$139m in its upcoming India IPO. The deal will be run by Axis and IIFL.
- ALL is a leading vertically integrated Indian player in the lab-grown diamond (LGD) industry, as per Wazir report.
- As of FY26, it was a leading global MPCVD machine manufacturer for LGD production, with an estimated 36% global volume market share, as per Wazir report.
IPO Databook: Amicro Technology (HK) – Sep 2026
- Amicro Technology Co., Ltd. is a robotics technology platform provider offering intelligent mobile robotics solutions, including inertial, single-modal, and multi-modal robotic solutions.
- Amicro Technology ranked third in China’s intelligent mobile robotic solutions market by revenue in 2025 and held 1,363 intellectual property rights.
- Amicro Technology reported losses for 2025 and the four months ended April 30, 2026, with gross profit margin decreasing to 23.9%.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: GEN Restaurant Group (GENK US) – Sep 2026
- GEN Restaurant Group is an Asian casual dining concept founded in 2011, offering Korean food through 54 restaurants and a growing CPG division.
- The company’s CPG division represents its single largest opportunity for near-term growth, with products now in nearly 2,000 retail doors nationwide.
- While the CPG division is a key growth opportunity, the company may require additional financing to sustain its operations.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: Laris Growth Acquisition (LARSU US) – Sep 2026
- Laris Growth Acquisition Corp. is a blank check company formed to effect a business combination, focusing on high-growth deep-tech businesses with compelling valuation arbitrage and need for scaled growth capital.
- The company focuses on high-growth deep-tech businesses in Quantum Computing, Next-Generation Space, and Intelligent Autonomous Systems across Europe, Australia/New Zealand, and the United States.
- As of May 31, 2026, the company reported $3,062 in working capital and shareholders’ equity, but public shareholders face approximately 108.7% dilution upon closing.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
IPO Databook: Acrobiosystems (301080 HK) – Sep 2026
- Acrobiosystems is principally engaged in the research and development, production, and sales of recombinant proteins, antibodies, and analytical assay kits, seeking a primary listing on the Stock Exchange of Hong.
- The company ranked first among China-based providers and third globally in the recombinant protein market by revenue in 2025, serving all top 20 global pharmaceutical companies.
- The company reported revenue of RMB838,118 thousand for FY2025, though profit for the year decreased from RMB147,552 thousand in 2023 to RMB120,042 thousand in 2024.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

